Lazard Asset Management
GLUE icon

Lazard Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Lazard Asset Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,857
Closed -$48K – 2014
2025
Q2 		$48K Buy
10,857
+3,262
+43% +$14.5K ﹤0.01% 2015
2025
Q1 		$35K Buy
+7,595
New +$46.6K ﹤0.01% 2054

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Lazard Asset Management's GLUE Position: Q3 2025 in Review

Lazard Asset Management sold out of Monte Rosa Therapeutics (GLUE) in Q3 2025, closing a stake of 10,857 shares — an estimated $48K sold.

Lazard Asset Management first reported a position in GLUE in Q1 2025 and held it in 2 quarters. The position peaked at $48K in Q2 2025. 129 funds tracked by Wall St. Rank hold GLUE as of Q3 2025.

  • Lazard Asset Management reported no remaining Monte Rosa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 10,857 Monte Rosa Therapeutics shares in Q3 2025, an estimated $48K.
  • Lazard Asset Management first reported a position in Monte Rosa Therapeutics in Q1 2025 and held it in 2 quarters.
  • Lazard Asset Management's Monte Rosa Therapeutics position peaked at $48K in Q2 2025.
  • 129 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.